• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

载体大小对昔萘酸沙美特罗从交互式混合物中分散的影响。

Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixtures.

作者信息

Islam Nazrul, Stewart Peter, Larson Ian, Hartley Patrick

机构信息

Department of Pharmaceutics, Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville Vic 3052, Australia.

出版信息

J Pharm Sci. 2004 Apr;93(4):1030-8. doi: 10.1002/jps.10583.

DOI:10.1002/jps.10583
PMID:14999738
Abstract

The objective of this study was to determine the influence of lactose carrier size on drug dispersion of salmeterol xinafoate (SX) from interactive mixtures. SX dispersion was measured by using the fine particle fractions determined by a twin stage impinger attached to a Rotahaler. The particle size of the lactose carrier in the SX interactive mixtures was varied using a range of commercial inhalation-grade lactoses. In addition, differing size fractions of individual lactose samples were achieved by dry sieving. The dispersion of SX appeared to increase as the particle size of the lactose carrier decreased for the mixtures prepared from different particle size commercial samples of lactose and from different sieve fractions of the same lactose. Fine particles of lactose (<5 microm) associated with the lactose carrier were removed from the carrier surface by a wet decantation process to produce lactose samples with low but similar concentrations of fine lactose particles. The fine particle fractions of SX in mixtures prepared with the decanted lactose decreased significantly (analysis of variance, p < 0.001) and the degree of dispersion became independent of the volume mean diameter of the carriers (analysis of variance, p < 0.05). The dispersion behavior is therefore associated with the presence of fine adhered particles associated with the carriers and the inherent size of the carrier itself has little influence on dispersion.

摘要

本研究的目的是确定乳糖载体大小对昔萘酸沙美特罗(SX)从交互式混合物中药物分散的影响。通过使用连接到旋转吸入器的双级撞击器测定的细颗粒部分来测量SX的分散度。使用一系列商业吸入级乳糖改变SX交互式混合物中乳糖载体的粒径。此外,通过干筛获得各个乳糖样品的不同粒度部分。对于由不同粒度的商业乳糖样品和同一乳糖的不同筛分级分制备的混合物,随着乳糖载体粒径的减小,SX的分散度似乎增加。通过湿倾析法从载体表面除去与乳糖载体相关的乳糖细颗粒(<5微米),以制备具有低但相似浓度的乳糖细颗粒的乳糖样品。用倾析乳糖制备的混合物中SX的细颗粒部分显著降低(方差分析,p <0.001),并且分散度变得与载体的体积平均直径无关(方差分析,p <0.05)。因此,分散行为与载体上附着的细颗粒的存在有关,而载体本身的固有尺寸对分散影响很小。

相似文献

1
Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixtures.载体大小对昔萘酸沙美特罗从交互式混合物中分散的影响。
J Pharm Sci. 2004 Apr;93(4):1030-8. doi: 10.1002/jps.10583.
2
Role of agglomeration in the dispersion of salmeterol xinafoate from mixtures for inhalation with differing drug to fine lactose ratios.凝聚在不同药物与乳糖比例的吸入用混合物中昔萘酸沙美特罗分散方面的作用。
J Pharm Sci. 2008 Aug;97(8):3140-52. doi: 10.1002/jps.21228.
3
Agglomerate strength and dispersion of salmeterol xinafoate from powder mixtures for inhalation.吸入用昔萘酸沙美特罗粉末混合物的团聚强度和分散性。
Pharm Res. 2006 Nov;23(11):2556-65. doi: 10.1007/s11095-006-9082-6. Epub 2006 Sep 14.
4
Lactose surface modification by decantation: are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose-interactive mixtures?沉淀法对乳糖表面的修饰:药物细粉乳糖比例是否是改善昔萘酸沙美特罗从乳糖相互作用混合物中分散性的关键?
Pharm Res. 2004 Mar;21(3):492-9. doi: 10.1023/B:PHAM.0000019304.91412.18.
5
Influence of the polydispersity of the added fine lactose on the dispersion of salmeterol xinafoate from mixtures for inhalation.添加的细乳糖的多分散性对昔萘酸沙美特罗从吸入用混合物中的分散度的影响。
Eur J Pharm Sci. 2009 Feb 15;36(2-3):265-74. doi: 10.1016/j.ejps.2008.10.001. Epub 2008 Oct 22.
6
Adhesion and redistribution of salmeterol xinafoate particles in sugar-based mixtures for inhalation.昔萘酸沙美特罗颗粒在吸入用糖基混合物中的黏附与再分布。
Int J Pharm. 2007 Jun 7;337(1-2):229-38. doi: 10.1016/j.ijpharm.2007.01.007. Epub 2007 Jan 14.
7
Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals.用于吸入丙酸氟替卡松和昔萘酸沙美特罗微晶的干粉制剂。
J Pharm Sci. 2009 Feb;98(2):503-15. doi: 10.1002/jps.21450.
8
Influence of storage relative humidity on the dispersion of salmeterol xinafoate powders for inhalation.储存相对湿度对吸入用昔萘酸沙美特罗粉分散性的影响。
J Pharm Sci. 2009 Mar;98(3):1015-27. doi: 10.1002/jps.21500.
9
Predicting the aerosol performance of dry powder inhalation formulations by interparticulate interaction analysis using inverse gas chromatography.通过使用反相气相色谱法的颗粒间相互作用分析预测干粉吸入制剂的气溶胶性能。
J Pharm Sci. 2006 Jan;95(1):228-33. doi: 10.1002/jps.20519.
10
Agglomerate properties and dispersibility changes of salmeterol xinafoate from powders for inhalation after storage at high relative humidity.高相对湿度储存后,吸入用粉雾剂中昔萘酸沙美特罗的聚集特性及分散性变化
Eur J Pharm Sci. 2009 Jun 28;37(3-4):442-50. doi: 10.1016/j.ejps.2009.03.016. Epub 2009 Apr 8.

引用本文的文献

1
Particle surface coating for dry powder inhaler formulations.用于干粉吸入剂制剂的颗粒表面包衣
Expert Opin Drug Deliv. 2025 May;22(5):711-727. doi: 10.1080/17425247.2025.2482052. Epub 2025 Mar 26.
2
Different Carriers for Use in Dry Powder Inhalers: Characteristics of Their Particles.干粉吸入器中使用的不同载体:其颗粒特性
J Aerosol Med Pulm Drug Deliv. 2024 Dec;37(6):307-327. doi: 10.1089/jamp.2023.0029. Epub 2024 Aug 9.
3
Dry powder inhaler design and particle technology in enhancing Pulmonary drug deposition: challenges and future strategies.
干粉吸入器设计和颗粒技术在增强肺部药物沉积中的作用:挑战与未来策略。
Daru. 2024 Dec;32(2):761-779. doi: 10.1007/s40199-024-00520-3. Epub 2024 Jun 11.
4
Optimization of Spray Drying Process Parameters for the Preparation of Inhalable Mannitol-Based Microparticles Using a Box-Behnken Experimental Design.使用Box-Behnken实验设计优化喷雾干燥工艺参数以制备可吸入的甘露醇基微粒
Pharmaceutics. 2023 Feb 2;15(2):496. doi: 10.3390/pharmaceutics15020496.
5
Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development.干粉吸入器设计与开发的进展及其对仿制药开发的潜在影响。
Pharmaceutics. 2022 Nov 17;14(11):2495. doi: 10.3390/pharmaceutics14112495.
6
The Optimisation of Carrier Selection in Dry Powder Inhaler Formulation and the Role of Surface Energetics.干粉吸入剂配方中载体选择的优化及表面能的作用
Biomedicines. 2022 Oct 26;10(11):2707. doi: 10.3390/biomedicines10112707.
7
Novel Pulmonary Delivery of Drugs for the Management of Atrial Fibrillation.新型肺部给药治疗心房颤动。
Am J Cardiovasc Drugs. 2023 Jan;23(1):1-7. doi: 10.1007/s40256-022-00551-8. Epub 2022 Oct 18.
8
Inhaled antibiotic-loaded polymeric nanoparticles for the management of lower respiratory tract infections.用于治疗下呼吸道感染的吸入式载抗生素聚合物纳米颗粒。
Nanoscale Adv. 2021 May 17;3(14):4005-4018. doi: 10.1039/d1na00205h. eCollection 2021 Jul 13.
9
Inhaled Edoxaban dry powder inhaler formulations: Development, characterization and their effects on the coagulopathy associated with COVID-19 infection.吸入型依度沙班干粉吸入剂制剂:研发、表征及其对 COVID-19 感染相关凝血障碍的影响。
Int J Pharm. 2021 Oct 25;608:121122. doi: 10.1016/j.ijpharm.2021.121122. Epub 2021 Sep 21.
10
Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization.葛根素干粉吸入制剂肺部给药系统的研究进展。
PLoS One. 2021 Apr 13;16(4):e0249683. doi: 10.1371/journal.pone.0249683. eCollection 2021.